Comprehensive molecular characterization of TFE3-rearranged renal cell carcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
초록
TFE3-rearranged renal cell cancer (tRCC) is a rare form of RCC that involves chromosomal translocation of the Xp11.2 TFE3 gene. Despite its early onset and poor prognosis, the molecular mechanisms of the pathogenesis of tRCC remain elusive. This study aimed to identify novel therapeutic targets for patients with primary and recurrent tRCC. We collected 19 TFE3-positive RCC tissues that were diagnosed by immunohistochemistry and subjected them to genetic characterization to examine their genomic and transcriptomic features. Tumor-specific signatures were extracted using whole exome sequencing (WES) and RNA sequencing (RNA-seq) data, and the functional consequences were analyzed in a cell line with TFE3 translocation. Both a low burden of somatic single nucleotide variants (SNVs) and a positive correlation between the number of somatic variants and age of onset were observed. Transcriptome analysis revealed that four samples (21.1%) lacked the expected fusion event and clustered with the genomic profiles of clear cell RCC (ccRCC) tissues. The fusion event also demonstrated an enrichment of upregulated genes associated with mitochondrial respiration compared with ccRCC expression profiles. Comparison of the RNA expression profile with the TFE3 ChIP-seq pattern data indicated that PPARGC1A is a metabolic regulator of the oncogenic process. Cell proliferation was reduced when PPARGC1A and its related metabolic pathways were repressed by its inhibitor SR-18292. In conclusion, we demonstrate that PPARGC1A-mediated mitochondrial respiration can be considered a potential therapeutic target in tRCC. This study identifies an uncharacterized genetic profile of an RCC subtype with unique clinical features and provides therapeutic options specific to tRCC.
Abstract
TFE3-rearranged renal cell cancer (tRCC) is a rare form of RCC that involves chromosomal translocation of the Xp11.2 TFE3 gene. Despite its early onset and poor prognosis, the molecular mechanisms of the pathogenesis of tRCC remain elusive. This study aimed to identify novel therapeutic targets for patients with primary and recurrent tRCC. We collected 19 TFE3-positive RCC tissues that were diagnosed by immunohistochemistry and subjected them to genetic characterization to examine their genomic and transcriptomic features. Tumor-specific signatures were extracted using whole exome sequencing (WES) and RNA sequencing (RNA-seq) data, and the functional consequences were analyzed in a cell line with TFE3 translocation. Both a low burden of somatic single nucleotide variants (SNVs) and a positive correlation between the number of somatic variants and age of onset were observed. Transcriptome analysis revealed that four samples (21.1%) lacked the expected fusion event and clustered with the genomic profiles of clear cell RCC (ccRCC) tissues. The fusion event also demonstrated an enrichment of upregulated genes associated with mitochondrial respiration compared with ccRCC expression profiles. Comparison of the RNA expression profile with the TFE3 ChIP-seq pattern data indicated that PPARGC1A is a metabolic regulator of the oncogenic process. Cell proliferation was reduced when PPARGC1A and its related metabolic pathways were repressed by its inhibitor SR-18292. In conclusion, we demonstrate that PPARGC1A-mediated mitochondrial respiration can be considered a potential therapeutic target in tRCC. This study identifies an uncharacterized genetic profile of an RCC subtype with unique clinical features and provides therapeutic options specific to tRCC.
참고문헌 (37)
- Wei, S., "Molecular characterization of TFE3-rearranged renal cell carcinoma : a comparative study with papillary and clear cell renal cell carcinomas", Mod. Pathol, 37, pp.100404~ (2024)
- Argani, P., "MiT family translocation renal cell carcinoma", Semin. Diagn. Pathol, 32, pp.103~113 (2015)
- Kauffman, E. C., "Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers", Nat. Rev. Urol, 11, pp.465~475 (2014)
- Malouf, G. G., "Transcription factor E3 and transcription factor EB renal cell carcinomas : clinical features, biological behavior and prognostic factors", J. Urol, 185, pp.24~29 (2011)
- Qiu Rao, "Renal cell carcinoma in children and young adults : clin icopathological, immunohistochemical, and VHL gene analysis of 46 cases with follow-up", Int. J. Surg. Pathol, 19, pp.170~179 (2011)
- Argani, P., "Xp11 translocation renal cell carcinoma in adults : expanded clinical, pathologic, and genetic spectrum", Am. J. Surg. Pathol, 31, pp.1149~1160 (2007)
- Komai, Y., "Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry", Clin. Cancer Res, 15, pp.1170~1176 (2009)
- Zhong, M., "Dual-color, break-apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma", Am. J. Surg. Pathol, 34, pp.757~766 (2010)
- Boilève, A., "Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders", J. Immunother. Cancer, 6, pp.159~ (2018)
- Kakoki, K., "Long-term treatment with sequential molecular targeted therapy for Xp11.2 translocation renal cell carcinoma: a case report and review of the literature", Clin. Genitourin. Cancer, 15, pp.e503~e506 (2017)
- Choueiri, T. K., "Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma", Cancer, 116, pp.5219~5225 (2010)
- Viale, A., "Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function", Nature, 514, pp.628~632 (2014)
- Lee, H., "Mitochondrial sirtuins : energy dynamics and cancer metabo lism", Mol. Cells, 47, pp.100029~ (2024)
- Martínez-Reyes, I., "Cancer metabolism : looking forward", Nat. Rev. Cancer, 21, pp.669~680 (2021)
- Schreiber, S. N., "The transcriptional coactivator PGC-1 regulates the expression and activity of the orphan nuclear receptor estrogen-related receptor α (ERRα)", J. Biol. Chem, 278, pp.9013~9018 (2003)
- Akgul, M., "Diagnostic approach in TFE3-rearranged renal cell carcinoma : a multi-institutional international survey", J. Clin. Pathol, 74, pp.291~299 (2021)
- "Scaling Accurate Genetic Variant Discovery to Tens of Thousands of Samples" (2017)[URL]
- Love, M. I., "Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2", Genome Biol, 15, pp.550~ (2014)
- Hu, X., "TumorFusions : an integrative resource for cancer-associated tran script fusions", Nucleic Acids Res, 46, pp.D1144~D1149 (2018)
- Ru, B., "MR4Cancer : a web server prioritizing master regulators for cancer", Bioinformatics, 35, pp.636~642 (2019)
- Ha, S. D., "Transcription-dependent targeting of Hda1C to hyperactive genes mediates H4-specific deacetylation in yeast", Nat. Commun, 10, pp.4270~ (2019)
- Langmead, B., "Fast gapped-read alignment with Bowtie 2", Nat. Methods, 9, pp.357~359 (2012)
- Zhang, Y., "Model-based Analysis of ChIP-Seq(MACS)", Genome Biol, 9, pp.R137~ (2008)
- Magers, M. J., "MiT family translocation-associated renal cell carcinoma: a contemporary update with emphasis on morphologic, immuno phenotypic, and molecular mimics", Arch. Pathol. Lab. Med, 139, pp.1224~1233 (2015)
- Cheng, J., "Computational analysis of pathological images enables a better diagnosis of TFE3 Xp11.2 translocation renal cell carcinoma", Nat. Commun, 11, pp.1778~ (2020)
- Margolin, A. A., "ARACNE : an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context", BMC Bioinforma, 7, pp.S7~ (2006)
- Sidhar, S., "The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene", Hum. Mol. Genet, 5, pp.1333~1338 (1996)
- Martina, J. A., "The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris", Sci. Signal, 7, pp.ra9~ (2014)
- Bakouny, Z., "Integrative clinical and molecular characterization of translo cation renal cell carcinoma", Cell Rep, 38, pp.110190~ (2022)
- Sharabi, K., "Selective chemical inhibition of PGC-1α gluconeogenic activity ameliorates type 2 diabetes", Cell, 169, pp.148~160 (2017)
- Choo, M. S., "Clinicopathologic characteristics and prognosis of Xp11.2translocation renal cell carcinoma: multicenter, propensity score matching ana lysis", Clin. Genitourin. Cancer, 15, pp.e819~e825 (2017)
- Argani, P., "Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions : a sensitive and specific immunohistochemical assay", Am. J. Surg. Pathol, 27, pp.750~761 (2003)
- Lee, H. J., "Combination of immunohistochemistry, FISH and RT-PCR shows high incidence of Xp11 translocation RCC : comparison of three different diag nostic methods", Oncotarget, 8, pp.30756~30765 (2017)
- Liberti, M. V., "The Warburg effect: how does it benefit cancer cells?", Trends Biochem. Sci, 41, pp.211~218 (2016)
- Škrtić, M., "Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia", Cancer Cell, 20, pp.674~688 (2011)
- Damayanti, N. P., "Therapeutic targeting of TFE3", IRS-1, mTOR axis in translocation renal cell carcinoma, pp.Clin. Cancer Res, 2018[DOI]
- Yin, X., "TFE3 fusions escape from controlling of mTOR signaling pathway and accumulate in the nucleus promoting genes expression in Xp11.2 translocation renal cell carcinomas", J. Exp. Clin. Cancer Res, 38, pp.119~ (2019)